Efficacy and safety of single-agent axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): a phase II trial

被引：0
|
作者：
Von Pawel, J. [1 ]
Larson, T. [2 ]
Ou, S. I. [3 ]
Limentani, S. A. [4 ]
Sandler, A. B. [5 ]
Vokes, E. E. [6 ]
Kim, S.
Liau, K. F.
Bycott, P. W. [7 ]
Schiller, J. H. [8 ]
机构：
[1] Asklepios Fachklin Lungenkrankheiten, Abt Onkol, Gauting, Germany
[2] Hubert H Humphrey Canc Ctr, Robbinsdale, MN USA
[3] Chao Family Comprehens Canc Ctr, Orange, CA USA
[4] Blumenthal Canc Ctr, Carolinas Hematol Oncol Assoc, Charlotte, NC USA
[5] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[6] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[7] Pfizer Inc, San Diego, CA USA
[8] Univ Texas Southwestern, Dallas, TX USA
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)71379-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6551
引用
收藏
页码：373 / 373
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety of patupilone in non-small cell lung cancer (NSCLC):: A phase I/II trial.
    Sanchez, J. M.
    Mellemgaard, A.
    Perry, M.
    Zatloukal, P.
    Hamm, J.
    Belani, C. P.
    Kim, E.
    Felip, E.
    Berton, M.
    Johri, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 390S - 390S
  • [32] Safety and efficacy of gefitinib monotherapy for patients (pts) ≥80 years (yrs) with advanced non-small cell lung cancer (NSCLC): A phase II subset analysis
    Ebi, N.
    Semba, H.
    Tokunaga, S.
    Takayama, K.
    Wataya, H.
    Kuraki, T.
    Yamamoto, H.
    Akamine, S.
    Okamoto, I.
    Nakanishi, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [33] Single-agent activity of gemcitabine in advanced non-small cell lung cancer
    LeChevalier, T
    SEMINARS IN ONCOLOGY, 1996, 23 (05) : 36 - 42
  • [34] Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: Pharmacokinetic and clinical results
    Rugo, HS
    Herbst, RS
    Liu, G
    Park, JW
    Kies, MS
    Steinfeldt, HM
    Pithavala, YK
    Reich, SD
    Freddo, JL
    Wilding, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) : 5474 - 5483
  • [35] A POPULATION PHARMACOKINETIC (PK)-PHARMACODYNAMIC (PD) ANALYSIS OF AXITINIB (AG-013736) EFFICACY AND TOLERABILITY ENDPOINTS IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (mCRC).
    Tortorici, M. A.
    Tarazi, J.
    Ricart, A. D.
    Cartwright, T.
    Bendell, J. C.
    Sobrero, A. F.
    Infante, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S78 - S78
  • [36] Efficacy of Single-Agent Chemotherapy after Exposure to Nivolumab in Advanced Non-Small Cell Lung Cancer
    Yasuda, Y.
    Funazo, T.
    Nomizo, T.
    Tsuji, T.
    Yoshida, H.
    Sakamori, Y.
    Nagai, H.
    Ozasa, H.
    Hirai, T.
    Kim, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2076 - S2076
  • [37] Phase I/II trial of gefitinib and RAD001 (everolimus) in patients (pts) with advanced non-small cell lung cancer (NSCLC).
    Milton, DT
    Kris, MG
    Azzoli, CG
    Gomez, JE
    Heelan, R
    Krug, LM
    Pao, W
    Pizzo, B
    Rizvi, NA
    Miller, VA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 646S - 646S
  • [38] A preliminary report of a phase II trial of single-agent vinflunine as second-line treatment of advanced non-small cell lung cancer
    Joppert, M.
    Boccia, R.
    Dakhil, S.
    Steis, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [39] Efficacy and Safety of Axitinib in Patients With Advanced Non-Small-Cell Lung Cancer: Results From a Phase II Study
    Schiller, Joan H.
    Larson, Timothy
    Ou, S-H. Ignatius
    Limentani, Steven
    Sandler, Alan
    Vokes, Everett
    Kim, Sinil
    Liau, Katherine
    Bycott, Paul
    Olszanski, Anthony J.
    von Pawel, Joachim
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (23) : 3836 - 3841
  • [40] KEY PREDICTIVE FACTORS OF AXITINIB (AG-013736)-INDUCED PROTEINURIA AND EFFICACY: A JAPANESE PHASE II STUDY IN PATIENTS WITH CYTOKINE-REFRACTORY METASTATIC RENAL CELL CANCER (MRCC)
    Tomita, Y.
    Uemura, H.
    Fujimoto, H.
    Kanayama, H.
    Shinohara, N.
    Nakazawa, H.
    Ozono, S.
    Naito, S.
    Akaza, H.
    ANNALS OF ONCOLOGY, 2010, 21 : 282 - 282
12345